<DOC>
	<DOCNO>NCT01509378</DOCNO>
	<brief_summary>The aim study characterize quantify relative effectiveness contribution implantable cardioverter defibrillator ( ICD ) therapy clinical outcome condition daily practice . Swiss , multicenter , prospective , observational study .</brief_summary>
	<brief_title>4P Study : Predictive Quality With Painfree Therapies</brief_title>
	<detailed_description>The main role ICD 's stop potentially lethal ventricular tachyarrhythmias overdrive pacing shock , reduce risk sudden cardiac death . The device program detect episode arrhythmias , classify accord threat patient , deliver therapy stop arrhythmia . The actual focus ICD program application fast-pacing therapy ( ATP antitachy pace ) first therapy apply shock last resort terminate episode . Some study show high success rate method decrease number shock deliver patient . Furthermore significant improvement do improve sensitivity specificity detection discrimination algorithm . This study focus late generation device performance review analyzed Adjudication Board .</detailed_description>
	<mesh_term>Arrhythmias , Cardiac</mesh_term>
	<criteria>Patients indication Protecta ICD CRTD device , later market release ICD ( first implant , replacement , upgrade ) Patients monitor Carelink monitoring system Patients sign patient inform consent form Patients older 18 year Patients young 18 year age Patients life expectancy le 24 month Females , pregnant child bear potential Patients participation another concomitant trial Patients unable willing provide sign patient inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ICD</keyword>
	<keyword>ATP therapy</keyword>
	<keyword>Rescue Shock therapy</keyword>
</DOC>